Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
AACE Clinical Case Reports
|
June 7, 2021
Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
Gayane Tumyan, Yogamaya Mantha, Rahul Gill, et al.
Journal of Clinical and Translational Science
|
January 12, 2026
Comparing survey delivery methods in healthcare: A randomized study
Gayane Tumyan, Kathleen Esselink, Ann Marie Navar, et al.
Cureus
|
March 30, 2022
Sebaceous Carcinoma Masquerading As Orbital Cellulitis
Vignesh Ramachandran, Gayane Tumyan, Asad Loya, et al.
Cancers
|
September 28, 2024
Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases
Oksana Hamidi, Mihailo Miljanic, Gayane Tumyan, et al.
The Lancet. Oncology
|
October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Tadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Leukemia & Lymphoma
|
January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia
Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2014
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study
Antonio Salar, Irit Avivi, Beate Bittner, et al.
Leukemia & Lymphoma
|
October 6, 2022
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study
Burhan Ferhanoglu, Tae Min Kim, Amado Karduss, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
Larry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
The Lancet. Haematology
|
November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
AACE Clinical Case Reports
|
June 7, 2021
Acute Sterile Meningitis as a Primary Manifestation of Pituitary Apoplexy
Gayane Tumyan, Yogamaya Mantha, Rahul Gill, et al.
Journal of Clinical and Translational Science
|
January 12, 2026
Comparing survey delivery methods in healthcare: A randomized study
Gayane Tumyan, Kathleen Esselink, Ann Marie Navar, et al.
Cureus
|
March 30, 2022
Sebaceous Carcinoma Masquerading As Orbital Cellulitis
Vignesh Ramachandran, Gayane Tumyan, Asad Loya, et al.
Cancers
|
September 28, 2024
Adrenal Insufficiency following Stereotactic Ablative Radiotherapy (SAbR) of Adrenal Gland Metastases
Oksana Hamidi, Mihailo Miljanic, Gayane Tumyan, et al.
The Lancet. Oncology
|
October 24, 2018
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Tadeusz Robak, Jie Jin, Halyna Pylypenko, et al.
Leukemia & Lymphoma
|
January 20, 2022
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia
Panayiotis Panayiotidis, Gayane Tumyan, Catherine Thieblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 14, 2014
Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study
Antonio Salar, Irit Avivi, Beate Bittner, et al.
Leukemia & Lymphoma
|
October 6, 2022
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC study
Burhan Ferhanoglu, Tae Min Kim, Amado Karduss, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 23, 2021
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
Larry W Kwak, Juan-Manuel Sancho, Seok-Goo Cho, et al.
The Lancet. Haematology
|
November 4, 2018
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Michinori Ogura, Juan Manuel Sancho, Seok-Goo Cho, et al.
Page
of 2